Skip to main content

Sarizotan Reference Vidi još Spoljašnje veze Мени за навигацију177975-08-569183882319847467LU0UCUW1223662410.1177/0269881102016003011598783410.1124/jpet.105.0871631739314410.1007/s00213-007-0762-7117232721476771510.1007/s00702-003-0094-71579163410.1002/mds.203701919654010.1016/j.parkreldis.2008.11.001ууу

АминиПиридиниОрганофлуоридиХромани


selektivniagonist5-HT1A receptorantagonistD2 receptoraantipsihotičkimdiskinezijuParkinsonove bolestilevodopomAzaperonBenperidolBromperidolDroperidolFluanizonHaloperidolLenperonMoperonPipamperonSpiperonTimiperonTrifluperidolKlopimozidFluspirilenPenfluridolPimozidAcepromazinAcetofenazinButaperazinKarfenazinHloracizinHlorproetazinHlorpromazinCijamemazinDiksirazinFluacizinFlufenazinLevomepromazin/MetotrimeprazinMezoridazinPerazinPericijazinPerfenazinPiperacetazinPipotiazinProhlorperazinPromazinPrometazinPropiomazinSulforidazinTietilperazinTiopropazatTioproperazinTioridazinTrifluoperazinTriflupromazinHlorprotiksenKlopentiksolFlupentiksolTiotiksenZuklopentiksolButaklamolFluotracenLoksapinTrimipraminCinuperonMelperonSetoperonIloperidonOkaperidonPaliperidonRisperidonLurasidonePerospironRevospironTiospironZiprasidonAmperozidAripiprazolBifeprunoksBrekspiprazolElopiprazolUmespironAmoksapinAsenapinKarpipraminKlocapraminKlorotepinKlotiapinKlozapinFluperlapinGevotrolinMetitepinMosapraminNDMCOlanzapinPihindonKvetijapinTenilapinZotepinWHO-EMPovučeniKlinička ispitivanjaFaza IIINije dospeo do faze IIIMPSOPSImeprdsrdodbpasspecspvoprocN5A5B5C6A6B6D










(function()var node=document.getElementById("mw-dismissablenotice-anonplace");if(node)node.outerHTML="u003Cdiv class="mw-dismissable-notice"u003Eu003Cdiv class="mw-dismissable-notice-close"u003E[u003Ca tabindex="0" role="button"u003Eсакријu003C/au003E]u003C/divu003Eu003Cdiv class="mw-dismissable-notice-body"u003Eu003Cdiv id="localNotice" lang="sr" dir="ltr"u003Eu003Cdiv class="noticebanner"u003Eu003Cdiv class="plainlinks" style="background-image: -moz-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -o-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -webkit-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: linear-gradient(to bottom, #fefefe, #fefefe, #f0f0f0);; -moz-border-radius: 10px; -webkit-border-radius: 10px; border-radius:10px; margin-top:10px; position:relative; height:25px; border-style:solid; border-width:1px; color:#aaa; border-color:u0026#32;; border:; font-family: u0026#39;Helveticau0026#39;, u0026#39;Arialu0026#39;, sans-serif; line-height: 18px; background-color:; overflow:hidden;"u003Eu003Cdiv style="display:block; position: absolute; top:4px; width:100%; text-align:center;;"u003Eu003Cdiv style="font-weight:bold; color:#000085; font-size:14px; line-height:25px"u003Eu003Cdiv style="padding-left:50px;"u003Eu003C/divu003Eu003C/divu003Eu003Cdiv style="margin-top: 2px; font-weight:normal; color:#555; font-size:15px; line-height:15px;"u003Eu003Cdiv style="padding-left:50px;"u003EУчествуј у u003Cbu003Eu003Ca href="https://meta.wikimedia.org/wiki/%D0%92%D0%B5%D0%BB%D0%B8%D0%BA%D0%BE_%D0%BF%D1%80%D0%BE%D0%BB%D0%B5%D1%9B%D0%BD%D0%BE_%D1%81%D1%80%D0%B5%D1%92%D0%B8%D0%B2%D0%B0%D1%9A%D0%B5_%D0%9E%D1%81%D1%82%D0%B0%D0%B2%D0%B5" class="extiw" title="meta:Велико пролећно сређивање Оставе"u003EВеликом пролећном сређивању Оставеu003C/au003Eu003C/bu003E од 15. марта до 15. априла!u003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Enu003Cdiv class="noticebanner"u003Eu003Cdiv class="plainlinks" style="background-image: -moz-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -o-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -webkit-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: linear-gradient(to bottom, #fefefe, #fefefe, #f0f0f0);; -moz-border-radius: 10px; -webkit-border-radius: 10px; border-radius:10px; margin-top:10px; position:relative; height:25px; border-style:solid; border-width:1px; color:#aaa; border-color:u0026#32;; border:; font-family: u0026#39;Helveticau0026#39;, u0026#39;Arialu0026#39;, sans-serif; line-height: 18px; background-color:; overflow:hidden;"u003Eu003Cdiv style="display:block; position: absolute; top:4px; width:100%; text-align:center;;"u003Eu003Cdiv style="font-weight:bold; color:#000085; font-size:14px; line-height:25px"u003Eu003Cdiv style="padding-left:50px;"u003Eu003C/divu003Eu003C/divu003Eu003Cdiv style="margin-top: 2px; font-weight:normal; color:#555; font-size:15px; line-height:15px;"u003Eu003Cdiv style="padding-left:50px;"u003EТакмичи се у писању u003Cbu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%A2%D0%B0%D0%BA%D0%BC%D0%B8%D1%87%D0%B5%D1%9A%D0%B5_%D1%83_%D0%BF%D0%B8%D1%81%D0%B0%D1%9A%D1%83_%D1%87%D0%BB%D0%B0%D0%BD%D0%B0%D0%BA%D0%B0/%D0%A6%D0%95%D0%95_%D0%BF%D1%80%D0%BE%D0%BB%D0%B5%D1%9B%D0%B5_2019" title="Википедија:Такмичење у писању чланака/ЦЕЕ пролеће 2019"u003Eчланака о средњој и источној Европиu003C/au003Eu003C/bu003E од 21. марта до 31. маја!u003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Enu003Cdiv class="noticebanner"u003Eu003Cdiv class="plainlinks" style="background-image: -moz-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -o-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -webkit-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: linear-gradient(to bottom, #fefefe, #fefefe, #f0f0f0);; -moz-border-radius: 10px; -webkit-border-radius: 10px; border-radius:10px; margin-top:10px; position:relative; height:25px; border-style:solid; border-width:1px; color:#aaa; border-color:u0026#32;; border:; font-family: u0026#39;Helveticau0026#39;, u0026#39;Arialu0026#39;, sans-serif; line-height: 18px; background-color:; overflow:hidden;"u003Eu003Cdiv style="display:block; position: absolute; top:4px; width:100%; text-align:center;;"u003Eu003Cdiv style="font-weight:bold; color:#000085; font-size:14px; line-height:25px"u003Eu003Cdiv style="padding-left:50px;"u003Eu003C/divu003Eu003C/divu003Eu003Cdiv style="margin-top: 2px; font-weight:normal; color:#555; font-size:15px; line-height:15px;"u003Eu003Cdiv style="padding-left:50px;"u003EУ току је расправа о u003Cbu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9F%D1%80%D0%B5%D0%B4%D0%BB%D0%BE%D0%B3/%D0%9F%D1%80%D0%B0%D0%B2%D0%BE_%D0%B0%D0%B4%D0%BC%D0%B8%D0%BD%D0%B8%D1%81%D1%82%D1%80%D0%B0%D1%82%D0%BE%D1%80_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D1%84%D0%B5%D1%98%D1%81%D0%B0" title="Википедија:Гласање/Предлог/Право администратор интерфејса"u003Eадминистраторима интерфејсаu003C/au003Eu003C/bu003E.u003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Enu003Cdiv class="noticebanner"u003Eu003Cdiv class="plainlinks" style="background-image: -moz-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -o-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: -webkit-linear-gradient(top, #fefefe, #fefefe, #f0f0f0); background-image: linear-gradient(to bottom, #fefefe, #fefefe, #f0f0f0);; -moz-border-radius: 10px; -webkit-border-radius: 10px; border-radius:10px; margin-top:10px; position:relative; height:25px; border-style:solid; border-width:1px; color:#aaa; border-color:u0026#32;; border:; font-family: u0026#39;Helveticau0026#39;, u0026#39;Arialu0026#39;, sans-serif; line-height: 18px; background-color:; overflow:hidden;"u003Eu003Cdiv style="display:block; position: absolute; top:4px; width:100%; text-align:center;;"u003Eu003Cdiv style="font-weight:bold; color:#000085; font-size:14px; line-height:25px"u003Eu003Cdiv style="padding-left:50px;"u003Eu003C/divu003Eu003C/divu003Eu003Cdiv style="margin-top: 2px; font-weight:normal; color:#555; font-size:15px; line-height:15px;"u003Eu003Cdiv style="padding-left:50px;"u003EУ току су гласања о u003Cbu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9F%D0%BE%D0%B2%D0%B5%D1%9B%D0%B0%D1%9A%D0%B5_%D0%BF%D1%80%D0%BE%D1%81%D1%82%D0%BE%D1%80%D0%B0_%D0%B7%D0%B0_%D1%81%D0%BB%D0%B8%D0%BA%D0%B5_%D0%BD%D0%B0_%D0%B3%D0%BB%D0%B0%D0%B2%D0%BD%D0%BE%D1%98_%D1%81%D1%82%D1%80%D0%B0%D0%BD%D0%B8" title="Википедија:Гласање/Повећање простора за слике на главној страни"u003Eповећању простора за слике на Главној страниu003C/au003Eu003C/bu003E и u003Cbu003Eu003Ca href="/wiki/%D0%92%D0%B8%D0%BA%D0%B8%D0%BF%D0%B5%D0%B4%D0%B8%D1%98%D0%B0:%D0%93%D0%BB%D0%B0%D1%81%D0%B0%D1%9A%D0%B5/%D0%9F%D1%80%D0%B0%D0%B2%D0%B8%D0%BB%D0%B0_%D0%B7%D0%B0_%D0%BA%D0%BE%D1%80%D0%B8%D1%88%D1%9B%D0%B5%D1%9A%D0%B5_%D0%B8%D0%BC%D0%B5%D0%BD%D1%81%D0%BA%D0%BE%D0%B3_%D0%BF%D1%80%D0%BE%D1%81%D1%82%D0%BE%D1%80%D0%B0_%D0%9D%D0%B0%D1%86%D1%80%D1%82" title="Википедија:Гласање/Правила за коришћење именског простора Нацрт"u003Eкоришћењу именског простора Нацртu003C/au003Eu003C/bu003E.u003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003Eu003C/divu003E";());




Sarizotan




Из Википедије, слободне енциклопедије






Иди на навигацију
Иди на претрагу





















Sarizotan
Sarizotan.png

IUPAC ime
1-[(2R)-3,4-dihidro-2H-hromen-2-il]-N-([5-(4-fluorofenil)pyridin-3-il]metil)metanamin
Klinički podaci
Kategorija trudnoće

  • N/A
Način primeneOralno
Identifikatori
CAS broj
177975-08-5 ДаY
ATC kodnone
PubChemCID 6918388
ChemSpider2319847
UNII
467LU0UCUW ДаY
Hemijski podaci
Formula
C22H21FN2O
Molarna masa348,413 g/mol



Sarizotan (EMD-128,130) je selektivni agonist 5-HT1A receptor i antagonist D2 receptora,[1] sa antipsihotičkim dejstvom.[2][3] Takođe je poznato da redukuje diskineziju kod dugotrajnih tretmana Parkinsonove bolesti sa levodopom.[4][5][6][7]



Reference




  1. ^ Rabiner, E. A.; Gunn, R. N.; Wilkins, M. R.; Sedman, E.; Grasby, P. M. (2002). „Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with 11CWAY-100635 and 11Craclopride”. Journal of psychopharmacology (Oxford, England). 16 (3): 195—199. PMID 12236624. doi:10.1177/026988110201600301. }


  2. ^ Assié, M.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. (2005). „Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain”. The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 265—272. PMID 15987834. doi:10.1124/jpet.105.087163. 


  3. ^ Auclair, A.; Galinier, A.; Besnard, J.; Newman-Tancredi, A.; Depoortère, R. (2007). „Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats”. Psychopharmacology. 193 (1): 45—54. PMID 17393144. doi:10.1007/s00213-007-0762-7. 


  4. ^ Bibbiani, F.; Oh, J. D.; Chase, T. N. (2001). „Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models”. Neurology. 57 (10): 1829—1834. PMID 11723272. 


  5. ^ Bartoszyk, G.; Van Amsterdam, C.; Greiner, H.; Rautenberg, W.; Russ, H.; Seyfried, C. (2004). „Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile”. Journal of neural transmission (Vienna, Austria : 1996). 111 (2): 113—126. PMID 14767715. doi:10.1007/s00702-003-0094-7. 


  6. ^ Bara-Jimenez, W.; Bibbiani, F.; Morris, M.; Dimitrova, T.; Sherzai, A.; Mouradian, M.; Chase, T. (2005). „Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease”. Movement disorders : official journal of the Movement Disorder Society. 20 (8): 932—936. PMID 15791634. doi:10.1002/mds.20370. 


  7. ^ Grégoire, L.; Samadi, P.; Graham, J.; Bédard, P.; Bartoszyk, G.; Di Paolo, T. (2009). „Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys”. Parkinsonism & related disorders. 15 (6): 445—452. PMID 19196540. doi:10.1016/j.parkreldis.2008.11.001. 



Vidi još


  • Osemozotan

  • Piklozotan

  • Robalzotan


Spoljašnje veze














Преузето из „https://sr.wikipedia.org/w/index.php?title=Sarizotan&oldid=12331839”










Мени за навигацију


























(window.RLQ=window.RLQ||[]).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.880","walltime":"1.020","ppvisitednodes":"value":5860,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":551353,"limit":2097152,"templateargumentsize":"value":64674,"limit":2097152,"expansiondepth":"value":17,"limit":40,"expensivefunctioncount":"value":0,"limit":500,"unstrip-depth":"value":0,"limit":20,"unstrip-size":"value":10717,"limit":5000000,"entityaccesscount":"value":0,"limit":400,"timingprofile":["100.00% 644.745 1 -total"," 36.32% 234.180 1 Шаблон:Drugbox-lat"," 32.13% 207.181 2 Шаблон:Infobox"," 25.02% 161.303 1 Шаблон:Reflist"," 23.28% 150.125 2 Шаблон:Navbox_with_collapsible_sections"," 21.59% 139.220 7 Шаблон:Cite_journal"," 12.98% 83.659 1 Шаблон:Dopaminergici-lat"," 12.24% 78.890 16 Шаблон:Navbox_subgroup"," 12.08% 77.914 1 Шаблон:Serotonergici-lat"," 7.01% 45.228 1 Шаблон:Antipsihotici-lat"],"scribunto":"limitreport-timeusage":"value":"0.257","limit":"10.000","limitreport-memusage":"value":5058016,"limit":52428800,"cachereport":"origin":"mw1330","timestamp":"20190401225231","ttl":2592000,"transientcontent":false);mw.config.set("wgBackendResponseTime":139,"wgHostname":"mw1320"););

Popular posts from this blog

ParseJSON using SSJSUsing AMPscript with SSJS ActivitiesHow to resubscribe a user in Marketing cloud using SSJS?Pulling Subscriber Status from Lists using SSJSRetrieving Emails using SSJSProblem in updating DE using SSJSUsing SSJS to send single email in Marketing CloudError adding EmailSendDefinition using SSJS

Кампала Садржај Географија Географија Историја Становништво Привреда Партнерски градови Референце Спољашње везе Мени за навигацију0°11′ СГШ; 32°20′ ИГД / 0.18° СГШ; 32.34° ИГД / 0.18; 32.340°11′ СГШ; 32°20′ ИГД / 0.18° СГШ; 32.34° ИГД / 0.18; 32.34МедијиПодациЗванични веб-сајту

19. јануар Садржај Догађаји Рођења Смрти Празници и дани сећања Види још Референце Мени за навигацијуу